Correction: Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score® test among node-negative early breast cancer patients in Japan
Kei Koizumi, Ataru Igarashi, Mark Gouldson, Sandeep Bilthare et autres
0 citationsBreast Cancer
Kei Koizumi
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
40Publications signalées
625Citations signalées
2Affiliations récentes
Institutions déclarées
Domaines associés
Breast Cancer Treatment StudiesAdvanced Breast Cancer TherapiesCancer Treatment and PharmacologyHER2/EGFR in Cancer ResearchBreast Lesions and Carcinomas
Publications récentes
Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALD
Norikazu Masuda, Shigehira Saji, Yasuyuki Kojima, Masahiro Kitada et autres
0 citationsBreast Cancer Research and Treatment
Quality-of-life assessment in the randomized JBCRG-M06/EMERALD study of eribulin plus dual HER2 blockade in HER2-positive locally advanced or metastatic breast cancer
Tsuguo Iwatani, Norikazu Masuda, Shigehira Saji, Takuhiro Yamaguchi et autres
0 citationsBreast Cancer
Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score® test among node-negative early breast cancer patients in Japan
Kei Koizumi, Ataru Igarashi, Mark Gouldson, Sandeep Bilthare et autres
0 citationsBreast Cancer
Health-related quality of life and physical activity collected via mobile application and wearable device in patients with HR +/HER2 − advanced breast cancer treated with palbociclib plus endocrine therapy or endocrine therapy alone: 6-month longitudinal study (JBCRG-26)
Hiroko Bando, Aya Ueda, Kaori Terata, Mihoko Doi et autres
2 citationsBreast Cancer
Correction: Real‑world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first‑ or second‑line treatment for hormone receptor–positive, HER2‑negative advanced or metastatic breast cancer
Tetsuhiro Yoshinami, Yuko Takano, Yukinori Ozaki, Yukiko Kajiwara et autres
0 citationsBreast Cancer
Abstract P4-10-03: Potential risk factors for health-related quality of life (HRQoL) in palbociclib (PAL) plus endocrine therapy (ET) and ET alone patients with HR+/HER2- advanced breast cancer (ABC): exploratory analysis from 6-month longitudinal study (JBCRG-26)
Shigehira Saji, Mari S. Oba, Aya Ueda, Kaori Terata et autres
0 citationsClinical Cancer Research
Abstract P4-11-07: The Oncotype DX® test to guide adjuvant chemotherapy treatment decisions for early node-negative HR+/HER2- breast cancer patients in Japan: a cost-effectiveness analysis
Kei Koizumi, Tobiasz Lemański, Gebra Cuyún Carter, S. Eymere et autres
0 citationsClinical Cancer Research
Real-world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first- or second-line treatment for hormone receptor–positive, HER2-negative advanced or metastatic breast cancer
Tetsuhiro Yoshinami, Yuko Takano, Yukinori Ozaki, Yukiko Kajiwara et autres
5 citationsBreast Cancer
Imaging of breast cancer using reflectance diffuse optical tomography (RDOT)
Nobuko Yoshizawa, Yuko Asano, Kenji Yoshimoto, Hiroko Wada et autres
0 citationsOptical Review
Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2–Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial
Toshinari Yamashita, Shigehira Saji, Toshimi Takano, Yoichi Naito et autres
12 citationsJournal of Clinical Oncology
A multicenter, phase II trial of triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for highly emetogenic chemotherapy in breast cancer (PATROL-II)
Kenichi Suzuki, Takashi Yokokawa, Takashi Kawaguchi, Shinya Takada et autres
1 citationScientific Reports
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, ROR et la Banque mondiale, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune donnée externe enregistrée en base. Sources et limites.